TY - JOUR
TI - Patients’ preferences for headache acute and preventive treatment
AU - Mitsikostas, D.D.
AU - Belesioti, I.
AU - Arvaniti, C.
AU - Mitropoulou, E.
AU - Deligianni, C.
AU - Kasioti, E.
AU - Constantinidis, T.
AU - Dermitzakis, M.
AU - Vikelis, M.
AU - on behalf of the Hellenic Headache Society
JO - The Journal of Headache and Pain
PY - 2017
VL - 18
TODO - 1
SP - null
PB - Springer-Verlag Italia s.r.l.
SN - 1129-2369, 1129-2377
TODO - 10.1186/s10194-017-0813-3
TODO - analgesic agent;  monoclonal antibody;  analgesic agent;  monoclonal antibody, adult;  Article;  chronic cluster headache;  chronic tension headache;  clinical article;  clinical effectiveness;  device safety;  drug safety;  episodic cluster headache;  episodic migraine;  episodic tension headache;  female;  human;  male;  nerve stimulation;  nerve stimulator;  nocebo effect;  outpatient;  patient preference;  priority journal;  prophylaxis;  prospective study;  Q No questionnaire;  questionnaire;  scoring system;  transformed migraine;  Greece;  headache;  implantable neurostimulator;  middle aged;  migraine;  patient preference;  preventive medicine;  psychology;  questionnaire;  subcutaneous drug administration;  utilization;  young adult, Adult;  Analgesics;  Antibodies, Monoclonal;  Female;  Greece;  Headache;  Humans;  Implantable Neurostimulators;  Injections, Subcutaneous;  Male;  Middle Aged;  Migraine Disorders;  Patient Preference;  Preventive Medicine;  Surveys and Questionnaires;  Young Adult
TODO - Background: We aimed to explore patients’ preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo. Methods: Questionnaires from 514 outpatients naïve to neurostimulation and monoclonal antibodies were collected. Results: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices. Conclusion: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person. © 2017, The Author(s).
ER -